

Review articles

Amoebas from the genus *Acanthamoeba* and their pathogenic properties

Karolina Kot, Natalia A. Łanocha-Arendarczyk, Danuta I. Kosik-Bogacka

Department of Biology and Medical Parasitology, Faculty of Medicine, Biotechnology and Laboratory Medicine, Pomeranian Medical University in Szczecin, ul. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland

Corresponding Author: Danuta I. Kosik-Bogacka; e-mail: kodan@pum.edu.pl

ABSTRACT. Amoebas from the genus *Acanthamoeba* are cosmopolitan organisms, which can exist as free-living organisms and as parasites within host tissue. *Acanthamoeba* infection present a serious risk to human health and are characterized by high mortality, especially in immunocompromised individuals. These protozoa are the etiological factors of granulomatous amoebic encephalitis (GAE) and *Acanthamoeba* keratitis (AK). They can also live in the lungs, adrenals glands, nose, throat, and bones of the host. Furthermore, the amoebas can be vectors of pathogenic bacteria. *Acanthamoeba* infection caused is a serious clinical problem mainly due to limited progress in diagnostics and treatment of this infection, which is associated with insufficient knowledge of pathogenesis, pathophysiology and the host immune response against *Acanthamoeba* antigens. This review study presents the biology of *Acanthamoeba* sp. as well as pathogenicity, diagnostics, and treatment of amoebas infections. It also presents data, including experimental results, concerning pathogenic properties and the host's immunology response against *Acanthamoeba* sp.

Key words: *Acanthamoeba* sp., diagnostics, treatment, pathogenesis, immunology response

Introduction

Amoebas from the genus *Acanthamoeba* pose a threat to human health and life, especially to persons with a lower immunity level. Due to the lack of appropriate diagnostic methods and effective treatment, *Acanthamoeba* infection are characterized by high mortality [1]. In addition, amoebas have the ability to transmit microbes that may show increased virulence and drug resistance [2]. There are many scientific studies on interactions between *Acanthamoeba* sp. and host. These studies are often conducted on animal models, mainly BALB/c and Swiss mice, but also on rats, hamsters, rabbits, pigs and locusts (*Locusta migratoria*) [3–6]. The pathomorphological and pathophysiological changes observed in these animals, especially in mice, are analogical to those found in humans. In addition, specific murine monoclonal antibodies are available commercially, which enables multidirectional studies [7].

Morphology of *Acanthamoeba* species

Acanthamoeba sp. are free-living protozoa that occur commonly in the natural environment. They are amphizoic organisms which can be either free-living or parasitic [8]. Amoebas can be found in trophozoite or cyst form. The trophozoite is 13–40 µm in diameter. The protozoa cells contains nucleus with central nucleolus, single pulsating vacuole and numerous digestive vacuoles. Spiny surface structures called acanthopodia or lobopodia are responsible for amoeboid movement [9]. After a period of intensive growth or as a result of unfavourable environmental conditions, trophozoite may transform into a cyst (encystation) which may retain its pathogenic properties even up to a dozen or so years [10,11]. Depending on the species, cysts have a round or polygonal shape and are surrounded by a double shell: the outer strongly pleated (ectocyst) and the smooth inner (endocyst) in a star-shaped or polygonal shape, which clearly protrudes from the outer shell in several places [12]. Cysts,

whose diameter usually does not exceed 25 μm , are resistant to many physical and chemical factors. They can survive at low temperatures, are resistant to drying out, ultraviolet radiation, variable osmotic pressure, changes in humidity, changes in the concentration of hydrogen ions as well as organic and inorganic compounds [9]. It has been shown that all development forms of amoebas are invasive to humans [13].

Genotypes of *Acanthamoeba* species

Initially, the identification of *Acanthamoeba* sp. was based on morphological features, including the size, shape of ecto- and endocysts and temperature requirements necessary for the growth of the organisms. Currently, the identification is conducted with the use of biochemical and molecular biology techniques [9,14,15]. To date, 22 genotypes (T1-T22) have been identified, based on the analysis of the 18S rRNA gene sequence using the polymerase chain reaction (PCR) [16]. It was found that *Acanthamoeba* sp. of the genus T2-T6 and T10, T11, and T15 are the etiologic factors of *Acanthamoeba* keratitis (AK), whereas the genotypes T1, T2, T4, T5, T10, and T12 are the factors of granulomatous amebic encephalitis (GAE) [17]. The latest identified genotypes include the environmental genotype T19 (*Acanthamoeba micheli*) [18] and the pathogenic genotype T20, which was initially classified as T4 [19] as well as genotypes T21 and T22 (T22 – *Acanthamoeba pyriformis*). However, genotypes T21 and T22 have not been published in the database yet [20]. The most commonly isolated strain of *Acanthamoeba* from patients with GAE and AK is *Acanthamoeba* T4, which is suggested to be characterized by increased virulence and reduced sensitivity to chemotherapeutic agents [12].

Occurrence of *Acanthamoeba* species

Acanthamoeba sp. are cosmopolitan protozoa, which are ubiquitous in natural environment. Natural antibodies against *Acanthamoeba* IgG have been found in peripheral blood in over 80% of human population [21]. The amoebas were isolated from water, soil and air. They can be found in natural and artificial water reservoirs [22], as well as in dust, fans, air-conditioning, lens fluids and medical equipment, including dental units and dialysis stations [23–25]. They were also observed

in sandboxes, fountains, communal sewage and tap water [25,26]. Amoeba strains were isolated from fruits, vegetables, plants, fungi and some animal species [22,27]. In addition, protozoa were isolated from biological materials, including bacterial cultures, gastric and intestinal lavage, cerebrospinal fluid (CSF), sputum, bronchoalveolar lavage (BAL), nasopharyngeal and fragments of liver, kidneys, spleen, lungs and corneal scrapings [8,28–30].

Pathogenic properties

Factors determining pathogenicity of amoebas were divided into direct and indirect factors [9]. The direct agents are the ability to adhere, phagocytosis, secretion of specific enzymes and acanthoporphin which is cytotoxic to human neurons and antibacterial activity against various bacterial strains by increasing the permeability of their membranes [31]. In highly pathogenic amoebas were observed highly activity of proteolytic enzymes, mainly serine and cysteine proteases allowing *Acanthamoeba* sp. infection to the corneal stromal cornea with accompanying inflammatory reactions, oedema or necrosis [9,32]. Hadaś [33] observed that pathogenic strains of free-living amoeba were characterized by high activity of collagenase, elastase, as well as peroxidase, and low activity of superoxide dismutase. Correlations were also found between the activity of prostaglandin synthetase and induction of *Acanthamoeba* sp. infection, but no relationship between the activity of catalase and the virulence and infectiveness was noticed [33].

Indirect factors include the ability to encyst, morphology of protozoa, tolerance to changing environmental conditions, ubiquity, biofilms, chemotaxis, host health and drug resistance [9]. The pathogenicity of *Acanthamoeba* sp. trophozoites may be due to the number of acanthopodia that allow contact with host cells. Pathogenic amoebas have about 100 acanthopodia on their surface, and non-pathogenic ones have around 20 acanthopodia [32]. In addition, it was found that amoebas lacking these structures do not bind to epithelial cells of the cornea [10]. Pathogenic *Acanthamoeba* sp. show increased thermal tolerance compared to non-pathogenic strains [29]. Amoebas with pathogenic properties are able to grow and develop at 42°C and above, which is most likely due to their high levels of heat shock proteins (HSP60 and HSP70) [34].

The ability of *Acanthamoeba* sp. to grow at high temperature, osmolality and pH correlates with pathogenicity, as well as with their prevalence in various environments [32]. However, non-pathogenic strains with high thermal tolerance and non-thermophilic non-pathogenic strains have been described in the literature [32,35].

Amoebas are vectors of many pathogenic bacteria that facilitate their growth as well as development and protect microbes from adverse environmental conditions and chemical factors [27]. It was found that 25% of *Acanthamoeba* sp. isolated from the environment are bacterial vectors. Free-living amoebae can be a reservoir of pathogenic bacteria such as *Vibrio cholerae*, *Mycobacterium tuberculosis*, *Yersinia enterocolitica*, *Escherichia coli*, *Enterobacter cloacae*, *Listeria monocytogenes*, *Helicobacter pylori*, *Legionella pneumophila*, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Stenotrophomonas maltophilia*, *Klebsiella pneumoniae*, *Serratia marcescens*, *Salmonella enterica*, *Shigella dysenteriae*, *Staphylococcus aureus*. Apart from bacteria, amoebae can also transmit fungi, protozoa and viruses [27,36].

The immune response of the host

In the available scientific literature, there is little data on the host's immune response to *Acanthamoeba* sp. infection. Studies have shown that infection with free-living amoebas induces both innate and adaptive immune responses [1].

An important role of recognizing *Acanthamoeba* sp. infection and inducing cytokine production, including interleukin 8 (IL-8), tumour necrosis factor (TNF- α) and interferon beta (IFN- β) in the host's body, is played by Toll-like receptors (TLRs) [37]. They are mainly associated with cells of the immune system and they occur on monocytes, macrophages, dendritic cells, B lymphocytes, eosinophils, neutrophils and mast cells [38]. TLR2 and TLR4 receptors are the best-known TLRs [15]. Increased levels of TLR2 and TLR4 mRNA expression were found in the lungs and brains of mice infected with *Acanthamoeba* sp., which may suggest the effect of these receptors on the initiation of the immune response [15,39]. Alizadeh et al. [40] demonstrated that the TLR4 receptor is responsible for the recognition of *Acanthamoeba* sp. These authors also observed an increase in the expression of this receptor in the cornea of hamsters infected with amoeba. The possibility for the parasite to be

recognized by TLR3 and TLR5, which are activated by double-stranded RNA and bacterial flagellin, respectively, is low because amoebae do not become intracellular and do not have flagellum [40].

The complement system is a barrier to many infections and works in a cascade system destroying bacteria and protozoa [41]. Activation of the complement system can occur either through the classic or alternative pathway, however the role of these proteins is not fully understood. *In vitro* studies with human serum showed that the complement and antibodies show lytic activity against *Acanthamoeba* sp. in the presence of phagocytes [42]. These reactions may stimulate the secretion of proinflammatory cytokines, including IL-1, IL-6 and TNF- α [43–45], which are released from monocytes and macrophages leading to the activation of neutrophils and vascular endothelial cells. It has been shown that TNF- α induces encystation of *Acanthamoeba* sp., which makes them resistant to phagocytosis [46]. Furthermore, it was found that trophozoites of pathogenic *Acanthamoeba* sp. are resistant to lysis through complementation due to the expression of regulatory proteins which exclude the complement cascade [47].

Phagocytic cells, such as neutrophils and macrophages, play a role in the destruction of *Acanthamoeba* sp. It has been found that macrophages may be involved in initiating and maintaining an effective immune response, but may also play a role in tissue repair processes [1]. *In vivo* studies concerning *Acanthamoeba* keratitis showed the presence of neutrophils in the brain and in the retina of the eye which may be involved in inhibiting the spread of invasion to other organs [48,49]. In mice infected with *Acanthamoeba* sp., a significant increase in natural killer (NK) cells was also observed, which suggests that these cells also participate in the protection of the body against these protozoa [50].

Animal studies have shown that subcutaneous immunization with trophozoites and cysts of *Acanthamoeba* sp. induces specific immunity in the form of delayed type hypersensitivity and the production of IgG antibodies [3]. Recent studies on the AK mouse model showed that an infection of amoebas induces T helper (Th) lymphocytes and regulatory T lymphocytes (Treg) in the cornea and the atopic lymph nodes. In addition, the *Acanthamoeba* sp. infection induces the expression of IL-17A which plays an important role in relieving the symptoms of ocular infection [51].

The intensity of inflammation depends on the functionality of the immune system, which may be regulated by the increased expression of cyclooxygenase (COX) [52]. Important mediators of the pathophysiology in experimental acanthamoebiasis occurred to be COX-1 and COX-2. *Acanthamoeba* sp. induced an expression of COX-1 and COX-2 proteins in the lungs of immunocompetent mice and a decrease in COX-1 and COX-2 in lung tissues in immunosuppressed *Acanthamoeba* sp. infected mice. However, it was also observed that expression of COX-1 and COX-2 proteins in the lungs of immunocompetent animals *Acanthamoeba* sp. infected does not correspond to differences in the expression of prostaglandin E₂ (PGE₂) and thromboxane B₂ (TXB₂) [53].

Pathogenesis of *Acanthamoeba* infection

Acanthamoeba sp. infections pose a threat to the health and life of the hosts. The infections are characterized by relatively high mortality despite low incidence [54]. Amoebae can cause cerebral and extracerebral infections concerning the cornea, lungs, kidneys and skin. The infection may develop in immunocompetent as well as immunocompromised patients [55].

Granulomatous amoebic encephalitis (GAE)

Granulomatous amoebic encephalitis is an opportunistic disease with mortality around 97-98%. Infection mostly occurs in people with metabolic, physiological and immunological disorders caused by e.g. HIV infection, and in persons with organ transplants or chronic diseases such as diabetes [30,56]. The main site of penetration is the olfactory epithelium in the nasal cavity, and the infection occurs through air inhalation or aspiration of water contaminated with invasive forms of the protozoan [13]. Trophozoites migrate to the central nervous system through the nasal mucous membrane, the endothelium of the capillaries of the brain and the ethmoid bone along the olfactory nerves [57]. The site of the infection may also include the oral mucosa, damaged or ulcerative skin, ocular cornea and intestinal mucosa [29]. The pathogenesis of infection is not precisely understood. Infection is chronic or subacute, with focal necrotic lesions leading to death after 8 days to several months after the onset of the first symptoms [58]. Clinical symptoms associated with the presence of parasites in the brainstem or midbrain

are psychiatric disorders, including confusion, lethargy and hallucinations. Patients with GAE also had headache, stiff neck, changes in body temperature, seizures and epileptic seizures, nausea and vomiting [59]. Clinical symptoms of GAE are not specific and the disease is often diagnosed as bacterial or viral encephalitis [27].

In the diagnosis of GAE, cerebrospinal fluid is used and lymphocytic pleocytosis, elevated protein levels and normal or reduced glucose are commonly observed [60]. Amoeba can also be isolated from the patient's tissues and grown *in vitro*. The material collected from the patient is placed on special culture media coated with inactivated bacteria, including *Escherichia coli* and *Enterobacter aerogenes*, with the plates subsequently incubated at 37°C [55]. Other methods used to identify *Acanthamoeba* sp. are immunodiagnostic and molecular methods, including PCR, real-time PCR and restriction fragment length polymorphism (RFLP) [9,61].

Treatment of brain infections caused by *Acanthamoeba* sp. is still difficult due to nonspecific symptoms and lack of diagnostic methods with high sensitivity and specificity. The treatment uses antibiotics used alone or combined therapy, including azole derivatives (fluconazole, ketoconazole, itraconazole, voriconazole), amphotericin B, rifampicin, pentamidine, sulfadiazine and flucytosine [62].

The first studies of *Acanthamoeba* sp. pathogenicity on experimental animals were conducted by Culbertson et al. [63]. Amoebas isolated from tissue culture were administered to mice using intracerebral and intravenous pathways. The study demonstrated extensive choroid plexus inflammation and meningitis as well as encephalomyelitis in the hosts [63]. Therefore, since the 1960s, various strains of laboratory mice have been used for *in vivo* experiments in experimental brain acanthamoebiasis. Previous studies demonstrated the presence of the following neurological symptoms in experimentally infected mice: erratic running in circles, hyperactivity and convulsions [60]. Histological and morphological analysis of the brain showed oedema, decreasing of fissures and a strong meningeal congestion. In addition, detachment of cerebral meninges from the cortical part of the cerebral hemispheres mainly in the frontal lobe region was observed [64].

***Acanthamoeba* keratitis (AK)**

The structure of the human eye and direct exposure to environmental factors make it susceptible to many infections, including *Acanthamoeba* sp. [65]. The first cases of amoeba infection into the cornea were described in 1974 [66], and more than 3,000 cases of AK have been described since then [25]. Persons using contact lenses are at the highest risk of infection [27,67]. Currently, about 90% of patients diagnosed with AK are persons using contact lenses [9,29]. Another risk factor is previous mechanical cornea injury combined with exposure to contaminated water or soil [68]. The etiological factors of the AK include: *A. castellani*, *A. polyphaga*, *A. rhyodes*, *A. culbertsoni*, *A. hatchetti*, *A. lugdunensis*, *A. quin* and *A. griffini* [32,69].

The first stage of *Acanthamoeba* infection is the adhesion of amoeba to epithelial cells of the host cornea. The elements involved in this process are acanthopodia and adhesins, including mannose-binding protein (MBP) and laminin-binding proteins [32,70]. Amoebae then penetrate the corneal epithelium causing phagocytosis and secretion of toxins responsible for the induction of apoptosis [10,71,72]. Protozoa secrete neuraminidase which plays a role in the colonization of the parasite [32] and proteases which lead to the degradation of basal membranes [12]. The mannose-induced cytopathic protein (MIP-133) is one of the serine proteases inducing degradation of keratocytes, ciliary body iris cells, retinal pigment epithelium, corneal epithelium and corneal endothelial cells [32]. Proteases allow the *Acanthamoeba* sp. infection. Into the cornea stroma with associated inflammatory reactions, oedema and necrosis [32]. The apoptotic bodies, changes in the cell membrane, chromatin condensation and DNA fragmentation can be observed in the infected cells of the corneal epithelium [9,22]. The last stage of the infection is corneal nerve inflammation [73].

Symptoms of AK include severe eye pain, blurred vision, photophobia, redness, foreign body sensation, followed by oedema of the conjunctiva and eyelids [32,74]. The inflammation of the lacrimal gland, extraocular muscle inflammation and have also been described [75]. Characteristic symptoms of the AK are single or multiple annular infiltrates in the central part of the cornea combined with the disappearance of keratocytes [32,65]. These changes usually occur within one eye, but cases of bilateral invasion have also been described

[76]. Advanced changes in the cornea can even lead to vision loss. Quick diagnostics and undertaking appropriate, long-term treatment allows to restore the proper functioning of the eye [77].

Acanthamoeba keratitis diagnosis is based on examination of corneal scrapings or material taken during corneal biopsies using haematoxylin and eosin staining, confocal microscopy and immunofluorescence methods [78,79]. It is not recommended to take swabs from the eyeball or tears, due to the rapid amoeba penetration into the subsequent layers of the cornea. In addition, similarly to GAE, breeding techniques and molecular methods are used [78,79].

Acanthamoeba keratitis treatment is difficult and long-lasting [80]. Propidium (0.1%), hexamidine, chlorhexidine (0.02%), neomycin, paromomycin, polynxin B, clotrimazole and itraconazole are used. Steroids are also used to relieve pain and reduce inflammation [27,81]. A recent report has demonstrated the effect of lactoferrin, an antimicrobial glycoprotein, on the survival and encystation of trophozoite of *Acanthamoeba* sp. which causes AK [82]. It was found that iron-free bovine milk lactoferrin (apo-bLF) has a potent amoebicidal effect on trophozoites, in contrast to iron-saturated bovine milk lactoferrin (Fe-bLF). Following the incubation of *Acanthamoeba* sp. with apo-bLF, most of the dead cells were found to be non-spherical amoeba trophozoites. On the other hand, apo-bLF did not show any amoebicidal effect on spherical trophozoites or cysts [82]. However, an *in vivo* study on mice by Hadaś et al. [83] found that tea tree oil can be used in the treatment of AK as it affects both trophozoites and cysts of *Acanthamoeba* sp. In addition, the study showed that the tea oil did not damage the cornea of the studied animals [83].

Most experimental studies on *Acanthamoeba* sp. infection are carried out on mice. However, Ren and Wu [7] found that it is preferable to study *Acanthamoeba* keratitis on rats than on mice. Although the amoebas penetrate the murine cornea more quickly than the rat cornea, the body size, level of immune response and limited range of anaesthetic doses increased the risk of death of mice [7]. However, recent reports indicate that the best model for experimental AK research is rabbit, as the morphological and anatomical structure of rabbit cornea is more similar to human cornea [84]. *Acanthamoeba* keratitis is induced in rabbits by amoeba microinjection to the area between the

corneal epithelium and Bowman's membrane. In contrast, amoeba injection into the stroma of corneal leads to a rapid inflammatory reaction, and in some animals can cause severe encephalitis [6].

***Acanthamoeba* sp. infection to other organs and tissues**

Infections caused by the *Acanthamoeba* sp. also affect the lungs, liver, kidneys, adrenal glands, heart, skin and bones [7,9,85]. These are rare infections, mainly occurring in immunosuppressed patients, including those after organ transplantation [25].

Cutaneous acanthamoebosis is characterized by spots and single or multiple nodules which can increase size and become ulcerated. Skin lesions mainly affect the face, trunk and limbs. The risk factors include postoperative scars, changes caused by chickenpox infection, bites and mechanical injuries [86]. Cutaneous acanthamoebosis, due to a similar clinical picture, is often mistaken for other skin diseases caused by bacteria, viruses, fungi or post-traumatic inflammatory changes. Frequent erroneous diagnosis of the disease results in mortality of approximately 70% [60,87]. Diagnosis is based primarily on the histopathological examination of the skin section, which contains granulocytes surrounding lymphocytes, giant cells, plasma cells, cutaneous and subcutaneous necrosis and neutrophil infiltrates [60]. In addition, immunofluorescence, breeding and PCR methods are used [27]. The treatment involves administration of chlorhexidine glucuronide and ketoconazole in combination with one of the following drugs: pentamidine isetate, sulfadiazine, flucytosine, fluconazole and thoraconazole [88]. Most of the cases of cutaneous acanthamoebosis reported to date concerned immunocompromised patients, but cases in immunocompetent patients have also been described [89].

Amoeba infections of the lung, liver and bone usually occur in patients with lower immunity levels. In patients with pulmonary acanthamoebosis, weight loss and decreased respiratory efficiency were observed while radiological examination revealed interstitial lesions with visible pulmonary oedema [90]. It was noticed that amoeba infection into the lungs can be bilateral with inconsistent infiltrations and is frequently accompanied by an already existing disease [91]. Diagnosis of the infection is usually performed *post-mortem* [8,85, 91,92].

Histopathological changes in the lungs, liver and kidneys of mice infected with *Acanthamoeba* sp. were described by Górnik and Kuźna-Grygiel [64]. In the lungs of the mice they found hyperplasia of the bronchiolar epithelium, thickening and congestion of the alveolar walls and trophozoites visible in the vascular walls. The authors observed extensive necrotic changes in the liver, accompanied by inflammatory infiltrates, polymorphism of hepatocyte nuclei and petechia, as well as extensive necrotic changes of the tubules and glomeruli and petechia in the kidneys [64].

In summary, *Acanthamoeba* sp. are cosmopolitan protozoa which pose a threat to the health and life of humans and animals due to their ability of development both inside and outside the host. As a result of their ubiquity, the widespread use of contact lenses and an increased number of persons with lower immunity levels, the incidence of *Acanthamoeba* sp. infection is likely to increase. More studies on the immunological and biochemical mechanism involved in the elimination of the parasite are necessary in order to fully elucidate the pathogenesis of diseases caused by the protozoa and to develop appropriate diagnostic and therapeutic strategies.

References

- [1] Cano A., Mattana A., Woods S., Henriquez F.L., Alexander J., Roberts C.W. 2017. *Acanthamoeba* activates macrophages predominantly through toll-like receptor 4- and MyD88-dependent mechanisms to induce interleukin-12 (IL-12) and IL-6. *Infection and Immunity* 85: e01054-16. doi:10.1128/iai.01054-16
- [2] Anacarso I., de Niederhäusern S., Messi P., Guerrieri E., Iseppi R., Sabia C., Bondi M. 2012. *Acanthamoeba polyphaga*, a potential environmental vector for the transmission of food-borne and opportunistic pathogens. *Journal of Basic Microbiology* 52: 261-268. doi:10.1002/jobm.201100097
- [3] Clarke D.W., Niederkorn J.Y. 2006. The immunobiology of *Acanthamoeba* keratitis. *Microbes and Infection* 8: 1400-1405. doi:10.1016/j.micinf.2005.12.009
- [4] Mortazavi P.N., Goldsworthy G., Kirk R., Khan N.A. 2010. *Acanthamoeba* produces disseminated infection in locusts and traverses the locust blood-brain barrier to invade the central nervous system. *BMC Microbiology* 10: 186. doi:10.1186/1471-2180-10-186
- [5] Gianinazzi C., Schild M., Zumkehr B., Wüthrich F., Nüesch I., Ryter R., Schürch N., Gottstein B., Müller

- N. 2010. Screening of Swiss hot spring resorts for potentially pathogenic free-living amoebae. *Experimental Parasitology* 126: 45-53. doi:10.1016/j.exppara.2009.12.008
- [6] Feng X., Zheng W., Wang Y., Zhao D., Jiang X., Lv S. 2015. A rabbit model of *Acanthamoeba* keratitis that better reflects the natural human infection. *Anatomical Record* 298: 1509-1517. doi:10.1002/ar.23154
- [7] Ren M., Wu X. 2010. Evaluation of three different methods to establish animal models of *Acanthamoeba* keratitis. *Yonsei Medical Journal* 51: 121-127. doi:10.3349/ymj.2010.51.1.121
- [8] Łanocha N., Kosik-Bogacka D., Maciejewska A., Sawczuk M., Wilk A., Kuźna-Grygiel W. 2009. The occurrence *Acanthamoeba* (free living amoeba) in environmental and respiratory samples in Poland. *Acta Protozoologica* 48: 271-279.
- [9] Khan N.A. 2006. *Acanthamoeba*: biology and increasing importance in human health. *FEMS Microbiology Reviews* 30: 564-595. doi:10.1111/j.1574-6976.2006.00023.x
- [10] Khan N.A., Tareen N.K. 2003. Genotypic, phenotypic, biochemical, physiological and pathogenicity-based categorisation of *Acanthamoeba* strains. *Folia Parasitologica* 50: 97-104. doi:10.14411/fp.2003.017
- [11] Mazur T., Hadaś E., Iwanicka I. 1995. The duration of the cyst stage and the viability and virulence of *Acanthamoeba* isolates. *Tropical Medicine and Parasitology* 46: 106-108.
- [12] Siddiqui R., Khan N.A. 2012. Biology and pathogenesis of *Acanthamoeba*. *Parasites and Vectors* 5: 6. doi:10.1186/1756-3305-5-6
- [13] Kasprzak W. 1985. Pełzaki wolnożyjące o właściwościach patogenicznych dla człowieka i zwierząt. Państwowe Wydawnictwo Naukowe, Warszawa (in Polish).
- [14] Kłopocka W., Rędownicz M.J., Wasik A. 2009. Regulacja dynamiki cytoszkieletu kortykalnego podczas migracji swobodnie żyjących ameb [Regulation of cortical cytoskeleton dynamics during migration of free-living amoebae]. *Postępy Biochemii* 55: 129-137 (in Polish with summary in English).
- [15] Derda M., Wojtkowiak-Giera A., Kolasa-Wołoskiuk A., Kosik-Bogacka D., Hadaś E., Jagodziński P.P., Wandurska-Nowak E. 2016. *Acanthamoeba* infection in lungs of mice expressed by toll-like receptors (TLR2 and TLR4). *Experimental Parasitology* 165: 30-34. doi:10.1016/j.exppara.2016.02.012
- [16] Taher E.E., Méabed E.M.H., Abdallah I., Abdel Wahed W.Y. 2018. *Acanthamoeba* keratitis in noncompliant soft contact lenses users: genotyping and risk factors, a study from Cairo, Egypt. *Journal of Infection and Public Health* 11: 377-383. doi:10.1016/j.jiph.2017.09.013
- [17] Behera H.S., Satpathy G., Tripathi M. 2016 Isolation and genotyping of *Acanthamoeba* spp. from *Acanthamoeba* meningitis/meningoencephalitis (AME) patients in India. *Parasites and Vectors* 9: 442. doi:10.1186/s13071-016-1729-5
- [18] Corsaro D., Walochnik J., Köhler M., Rott M.B. 2015. *Acanthamoeba* misidentification and multiple labels: redefining genotypes T16, T19, and T20 and proposal for *Acanthamoeba micheli* sp. nov. (genotype T19). *Parasitology Research* 114: 2481-2490. doi:10.1007/s00436-015-4445-8
- [19] Fuerst P.A., Booton G.C., Crary M. 2015. Phylogenetic analysis and the evolution of the 18S rRNA gene typing system of *Acanthamoeba*. *Journal of Eukaryotic Microbiology* 62: 69-84. doi:10.1111/jeu.12186
- [20] The Ohio State University. 2017. Genomes of *Acanthamoeba*. <https://u.osu.edu/acanthamoeba/genomes-of-acanthamoeba>
- [21] Brindley N., Matin A., Khan N.A. 2009. *Acanthamoeba castellanii*: high antibody prevalence in racially and ethnically diverse populations. *Experimental Parasitology* 121: 254-256. doi:10.1016/j.exppara.2008.11.009
- [22] Lorenzo-Morales J., Martín-Navarro C.M., López-Arencibia A., Arnalich-Montiel F., Piñero J.E., Valladares B. 2013. *Acanthamoeba* keratitis: an emerging disease gathering importance worldwide? *Trends in Parasitology* 29: 181-187. doi:10.1016/j.pt.2013.01.006
- [23] Khezri A., Fallah E., Mostafazadeh M., Spotin A., Shahbazi A., Mahami-Oskouci M., Hazratian T. 2016. Molecular and morphometric characterization of *Acanthamoeba* spp. from different water sources of northwest Iran as a neglected focus, co-bordec with the country of Iraq. *Jundishapur Journal of Microbiology* 9: e38481. doi:10.5812/jjm.38481
- [24] Tawfeek G.M., Bishara S.A.-H., Sarhan R.M., Taher E.E., Khayyal A.E. 2016. Genotyping, physiological and biochemical characterization of potentially pathogenic *Acanthamoeba* isolated from the environment in Cairo, Egypt. *Parasitology Research* 115: 1871-1881. doi:10.1007/s00436-016-4927-3
- [25] Król-Turmińska K., Olender A. 2017. Human infections caused by free-living amoebae. *Annals of Agricultural and Environmental Medicine* 24: 254-260. doi:10.5604/12321966.1233568
- [26] Cholewiński M., Hadaś E., Derda M., Wojt J.W., Skrzypczak Ł. 2013. Występowanie patogenicznych pełzaków wolno żyjących z rodzaju *Acanthamoeba* w piaskownicach miejskich [The occurrence of the pathogenic free-living amoeba from *Acanthamoeba* genus in city's sandboxes]. *Nowiny Lekarskie* 82: 138-141 (in Polish with summary in English).
- [27] Trabelsi H., Dendana F., Sellami A., Sellami H., Cheikhrouhou F., Neji S., Makni F., Ayadi A. 2012. Pathogenic free-living amoebae: epidemiology and clinical review. *Pathologie Biologie* 60: 399-405.

- doi:10.1016/j.patbio.2012.03.002
- [28] Berger P., Papazian L., Drancourt M., La Scola B., Auffray J.P., Raoult D. 2006. Ameba-associated microorganisms and diagnosis of nosocomial pneumonia. *Emerging Infectious Diseases* 12: 248-255. doi:10.3201/eid1202.050434
- [29] Visvesvara G.S., Moura H., Schuster F.L. 2007. Pathogenic and opportunistic free-living amoebae: *Acanthamoeba* spp., *Balamuthia mandrillaris*, *Naegleria fowleri* and *Sappinia diploidea*. *FEMS Immunology and Medical Microbiology* 50: 1-26. doi:10.1111/j.1574-695X.2007.00232.x
- [30] Memari F., Niyayati M., Joneidi Z. 2017. Pathogenic *Acanthamoeba* T4 genotype isolated from mucosal tissue of a patient with HIV infection: a case report. *Iranian Journal of Parasitology* 12: 143-147.
- [31] Michalek M., Sönnichsen F.D., Wechselberger R., Dingley A.J., Hung C.-W., Kopp A., Wienk H., Simanski M., Herbst R., Lorenzen I., Marciano-Cabral F., Gelhaus C., Gutschmann T., Tholey A., Grötzinger J., Leippe M. 2013. Structure and function of a unique pore-forming protein from a pathogenic *Acanthamoeba*. *Nature Chemical Biology* 9: 37-42.
- [32] Lorenzo-Morales J., Khan N.A., Walochnik J. 2015. An update on *Acanthamoeba* keratitis: diagnosis, pathogenesis and treatment. *Parasite* 22: 10. doi:10.1051/parasite/2015010
- [33] Hadaś E. 1993. Badania biochemiczne wykładników inwazyjności i wirulencji pełzaków z rodzaju *Acanthamoeba* [Study on biochemical exponents of *Acanthamoeba* invasiveness and virulence]. Akademia Medyczna, Poznań, Poland (in Polish).
- [34] Podlipaeva Yu.I., Shmakova L.A., Gilichinski D.A., Goodkov A.V. 2006. [Heat shock protein of HSP70 family revealed in some contemporary freshwater amoebae and in *Acanthamoeba* sp. excysted from cysts isolated from permafrost samples]. *Tsitologiya* 48: 691-694 (in Russian with summary in English).
- [35] Panjwani N. 2010. Pathogenesis of *Acanthamoeba* keratitis. *Ocular Surface* 8: 70-79. doi:10.1016/s1542-0124(12)70071-x
- [36] Thomas V., McDonnell G., Denyer S.P., Maillard J.-Y. 2010. Free-living amoebae and their intracellular pathogenic microorganisms: risks for water quality. *FEMS Microbiology Reviews* 34: 231-259. doi:10.1111/j.1574-6976.2009.00190.x
- [37] Ren M.Y., Wu X.Y. 2011. Toll-like receptor 4 signalling pathway activation in a rat model of *Acanthamoeba* Keratitis. *Parasite Immunol* 33: 25-33. doi:10.1111/j.1365-3024.2010.01247.x
- [38] Pachówka M., Kluk M., Korczak-Kowalska G. 2009. Rola receptorów Toll-podobnych (TLR) w indukcji i regulacji [Role of Toll-like receptors (TLR) in induction and regulation of immune response]. *Postępy Biologii Komórki* 36: 429-442 (in Polish with summary in English).
- [39] Wojtkowiak-Giera A., Derda M., Kolasa-Wołoski A., Hadaś E., Kosik-Bogacka D., Solarczyk P., Jagodziński P.P., Wandurska-Nowak E. 2016. Toll-like receptors in the brain of mice following infection with *Acanthamoeba* spp. *Parasitology Research* 115: 4335-4344. doi:10.1007/s00436-016-5217-9
- [40] Alizadeh H., Tripathi T., Abdi M., Smith A.D. 2014. Pathogenic strains of *Acanthamoeba* are recognized by TLR4 and initiated inflammatory responses in the cornea. *PLoS One* 9: e92375. doi:10.1371/journal.pone.0092375
- [41] Neelam S., Niederkorn J.Y. 2017. Pathobiology and Immunobiology of *Acanthamoeba* keratitis: insights from animal models. *Yale Journal of Biology and Medicine* 90: 261-268.
- [42] Ferrante A., Rowan-Kelly B. 1983. Activation of the alternative pathway of complement by *Acanthamoeba culbertsoni*. *Clinical and Experimental Immunology* 54: 477-485.
- [43] van Klink F., Alizadeh H., He Y., Mellon J.A., Silvany R.E., McCulley J.P., Niederkorn J.Y. 1993. The role of contact lenses, trauma, and Langerhans cells in a Chinese hamster model of *Acanthamoeba* keratitis. *Investigative Ophthalmology and Visual Science* 34: 1937-1944.
- [44] Benedetto N., Rossano F., Gorga F., Folgore A., Rao M., Romano Carratelli C. 2003. Defense mechanisms of IFN- γ and LPS-primed murine microglia against *Acanthamoeba castellanii* infection. *International Immunopharmacology* 3: 825-834. doi:10.1016/s1567-5769(03)00047-x
- [45] Stewart G.L., Shupe K., Kim I., Silvany R.E., Alizadeh H., McCulley J.P., Niederkorn J.Y. 1994. Antibody-dependent neutrophil-mediated killing of *Acanthamoeba castellanii*. *International Journal for Parasitology* 24: 739-742. doi:10.1016/0020-7519(94)90129-5
- [46] Mattana A., Sanna M., Cano A., Delogu G., Erre G., Roberts C.W., Henriquez F.L., Fiori P.L., Cappuccinelli P. 2016. *Acanthamoeba castellanii* genotype T4 stimulates the production of interleukin-10 as well as proinflammatory cytokines in THP-1 cells, human peripheral blood mononuclear cells, and human monocyte-derived macrophages. *Infection and Immunity* 84: 2953-2962. doi:10.1128/iai.00345-16
- [47] Toney D.M., Marciano-Cabral F. 1998. Resistance of *Acanthamoeba* species to complement lysis. *Journal of Parasitology* 84: 338-344. doi:10.2307/3284492
- [48] Harrison J.L., Ferreira G.A., Raborn E.S., Lafrenaye A.D., Marciano-Cabral F., Cabral G.A. 2010. *Acanthamoeba culbertsoni* elicits soluble factors that exert anti-microglial cell activity. *Infection and Immunity* 78: 4001-4011. doi:10.1128/iai.00047-10
- [49] Knickelbein J.E., Kovarik J., Dhaliwal D.K., Chu C.T. 2013. *Acanthamoeba* keratitis: a clinicopathologic case report and review of the literature. *Human Pathology* 44: 918-922.

- doi:10.1016/j.humpath.2012.10.007
- [50] Kim J.-Y., Na B.-K., Song K.-J., Park M.-H., Park Y.-K., Kim T.-S. 2012. Functional expression and characterization of an iron-containing superoxide dismutase of *Acanthamoeba castellanii*. *Parasitology Research* 111: 1673-1682. doi:10.1007/s00436-012-3006-7
- [51] Suryawanshi A., Cao Z., Sampson J.F., Panjwani N. 2015. IL-17A-mediated protection against *Acanthamoeba* keratitis. *Journal of Immunology* 194: 650-663. doi:10.4049/jimmunol.1302707
- [52] Ricciotti E., FitzGerald G.A. 2011. Prostaglandins and inflammation. *Arteriosclerosis, Thrombosis and Vascular Biology* 31: 986-1000. doi:10.1161/atvbaha.110.207449
- [53] Łanocha-Arendarczyk N., Baranowska-Bosiacka I., Kot K., Gutowska I., Kolasa-Wołoskiuk A., Chlubek D., Kosik-Bogacka D. 2018. Expression and activity of COX-1 and COX-2 in *Acanthamoeba* sp.-infected lungs according to the host immunological status. *International Journal of Molecular Sciences* 19: 121. doi:10.3390/ijms19010121
- [54] Diaz J.H. 2010. Increasing intracerebral infections caused by free-living amoebae in the United States and Worldwide. *Journal of Neuroparasitology* 1: 104. doi:10.4303/jnp/n100801
- [55] Łanocha-Arendarczyk N., Kosik-Bogacka D., Galant K., Zaorski W., Kot K., Łanocha A. 2017. Pełzaki wolno żyjące o właściwościach patogennych dla człowieka [Pathogenic free-living amoeba]. *Postępy Mikrobiologii* 56: 106-112 (in Polish with summary in English).
- [56] Salameh A., Bello N., Becker J., Zangeneh T. 2015. Fatal granulomatous amoebic encephalitis caused by *Acanthamoeba* in a patient with kidney transplant: a case report. *Open Forum Infectious Diseases* 2: ofv104. doi:10.1093/ofid/ofv104
- [57] Khan N.A., Siddiqui R. 2011. The neuro-pathogenesis of *Acanthamoeba* encephalitis: barriers to overcome. *Journal of Cell Science and Therapy* S3: 001. doi:10.4172/2157-7013.s3-001
- [58] Visvesvara G.S., Stehr-Green J.K. 1990. Epidemiology of free-living amoeba infections. *Journal of Protozoology* 37: 25s-33s. doi:10.1111/j.1550-7408.1990.tb01142.x
- [59] Martínez A.J., Visvesvara G.S. 2001. *Balamuthia mandrillaris* infection. *Journal of Medical Microbiology* 50: 205-207. doi:10.1099/0022-1317-50-3-205
- [60] Marciano-Cabral F., Cabral G. 2003. *Acanthamoeba* spp. as agents of disease in humans. *Clinical Microbiology Reviews* 16: 273-307. doi:10.1128/cmr.16.2.273-307.2003
- [61] Karsenti N., Lau R., Purssell A., Chong-Kit A., Cunanan M., Gasgas J., Tian J., Wang A., Ralevski F., Boggild A.K. 2017. Development and validation of a real-time PCR assay for the detection of clinical *acanthamoebae*. *BMC Research Notes* 10: 355. doi:10.1186/s13104-017-2666-x
- [62] Gupta R., Gorski M., Henderson T., Lazzaro D., Haseeb M.A. 2015. Clinical course of unilateral *Acanthamoeba* keratitis in a cosmetic contact lens wearer. *Annals of Clinical and Laboratory Science* 45: 366-370.
- [63] Culbertson C.G., Smith J.W., Minner J.R. 1958. *Acanthamoeba*: observations on animal pathogenicity. *Science* 127: 1506. doi:10.1126/science.127.3313.1506
- [64] Górník K., Kuźna-Grygiel W. 2005. Histological studies of selected organs of mice experimentally infected with *Acanthamoeba* spp. *Folia Morphologica* 64: 161-167.
- [65] Mahgoub A.M.A. 2010. *Acanthamoeba* keratitis. *Parasitologists United Journal* 3: 9-18.
- [66] Naginton J., Watson P.G., Playfair T.J., McGill J., Jones B.R., Steele A.D. 1974. Amoebic infection of the eye. *Lancet* 2: 1537-1540. doi:10.1016/S0140-6736(74)90285-2
- [67] Hadaś E., Derda M. 2013. Pełzakowe zapalenie rogówki oka - nowe zagrożenie epidemiologiczne [*Acanthamoeba* keratitis – the new epidemiological threat]. *Problemy Higieny i Epidemiologii* 94: 730-733 (in Polish with summary in English).
- [68] Wesołowska M., Cisowska A., Myjak P., Marek J., Jurowskaka-Liput J., Jakubaszko J. 2006. *Acanthamoeba* keratitis in contact lens wearers in Poland. *Advances in Clinical and Experimental Medicine* 15: 553-555.
- [69] Visvesvara G.S. 2010. Free-living amoebae as opportunistic agents of human disease. *Journal of Neuroparasitology* 1. doi:10.4303/jnp/N100802
- [70] Omaña-Molina M., Hernandez-Martinez D., Sanchez-Rocha R., Cardenas-Lemus U., Salinas-Lara C., Mendez-Cruz A.R., Colin-Barenque Lv, Aley-Medina P., Espinosa-Villanueva J., Moreno-Fierros L., Lorenzo-Morales J. 2017. In vivo CNS infection model of *Acanthamoeba* genotype T4: the early stages of infection lack presence of host inflammatory response and are a slow and contact-dependent process. *Parasitology Research* 116: 725-733. doi:10.1007/s00436-016-5338-1
- [71] Kong H.-H., Kim T.-H., Chung D.-I. 2000. Purification and characterization of a secretory serine proteinase of *Acanthamoeba* *healyi* isolated from GAE. *Journal of Parasitology* 86: 12-17. doi:10.2307/3284901
- [72] Sissons J., Kim K.S., Stins M., Jayasekera S., Alsam S., Khan N.A. 2005. *Acanthamoeba castellanii* induces host cell death via a phosphatidylinositol 3-kinase-dependent mechanism. *Infection and Immunity* 73: 2704-2708. doi:10.1128/iai.73.5.2704-2708.2005
- [73] Clarke B., Sinha A., Parmar D.N., Sykakis E. 2012. Advances in the diagnosis and treatment of

- Acanthamoeba* keratitis. *Journal of Ophthalmology* 2012; 484892. doi:10.1155/2012/484892
- [80] Wilhelmus K.R., Jones D.B., Matoba A.Y., Hamill M.B., Pflugfelder S.C., Weikert M.P. 2008. Bilateral *Acanthamoeba* keratitis. *American Journal of Ophthalmology* 145: 193-197. doi:10.1016/j.ajo.2007.09.037
- [81] Sengor T., Kurna S.A., Altun A., Irkeç M., Aki S.F., Aksoy S. 2015. Contact lens-related *Acanthamoeba* keratitis and accompanying dacryoadenitis. *Eye Contact Lens* 41: 204-209. doi:10.1097/icl.0000000000000114
- [82] Dart J.K.G., Saw V.P.J., Kilvington S. 2009. *Acanthamoeba* keratitis: diagnosis and treatment update 2009. *American Journal of Ophthalmology* 148: 487-499. doi:10.1016/j.ajo.2009.06.009
- [83] Prasher P., Sachdeva P., Ravinder N.B., Sachin W. 2004. *Acanthamoeba* keratitis: a review. *North Zone Ophthalmological Society* 14: 1-7.
- [84] Visvesvara G.S. 2013. Infections with free-living amebae. *Handbook of Clinical Neurology* 114: 153-168. doi:10.1016/b978-0-444-53490-3.00010-8
- [85] Walochnik J., Scheikl U., Haller-Schober E.-M. 2015. Twenty years of *Acanthamoeba* diagnostics in Austria. *Journal of Eukaryotic Microbiology* 62: 3-11. doi:10.1111/jeu.12149
- [86] Kaiserman I., Bahar I., McAllum P., Srinivasan S., Elbaz U., Slomovic A.R., Rootman D.S. 2012. Prognostic factors in *Acanthamoeba* keratitis. *Canadian Journal of Ophthalmology* 47: 312-317. doi:10.1016/j.cjco.2012.03.040
- [87] Seal D.V. 2003. *Acanthamoeba* keratitis update – incidence, molecular epidemiology and new drugs for treatment. *Eye* 17: 893-905. doi:10.1038/sj.eye.6700563
- [88] Tomita S., Suzuki C., Wada H., Nomachi M., Imayasu M., Araki-Sasaki K. 2017. Effects of lactoferrin on the viability and the encystment of *Acanthamoeba* trophozoites. *Biochemistry and Cell Biology* 95: 48-52. doi:10.1139/bcb-2016-0054
- [89] Hadaś E., Derda M., Cholewiński M. 2017. Evaluation of the effectiveness of tea tree oil in treatment of *Acanthamoeba* infection. *Parasitology Research* 116: 997-1001. doi:10.1007/s00436-017-5377-2
- [90] Zhou Q., Liu X.-Y., Ruan Y.-X., Wang L., Jiang M.-M., Wu J., Chen J. 2015. Construction of corneal epithelium with human amniotic epithelial cells and repair of limbal deficiency in rabbit models. *Human Cell* 28: 22-36. doi:10.1007/s13577-014-0099-6
- [91] Young A.L., LeBocuf N.R., Tsiouris S.J., Husain S., Grossman M.E. 2010. Fatal disseminated *Acanthamoeba* infection in a liver transplant recipient immunocompromised by combination therapies for graft-versus-host disease. *Transplant Infectious Disease* 12: 529-537. doi:10.1111/j.1399-3062.2010.00535.x
- [92] Sison J.P., Kemper C.A., Loveless M., McShane D., Visvesvara G.S., Deresinski S.C. 1995. Disseminated *Acanthamoeba* infection in patients with AIDS: case reports and review. *Clinical Infectious Diseases* 20: 1207-1216. doi:10.1093/clinids/20.5.1207
- [93] Torno Jr. M.S., Babapour R., Gurevitch A., Witt M.D. 2000. Cutaneous acanthamoebiasis in AIDS. *Journal of the American Academy of Dermatology* 42: 351-354. doi:10.1016/s0190-9622(00)90110-5
- [94] Walia R., Montoya J.G., Visvesvara G.S., Booton G.C., Doyle R.L. 2007. A case of successful treatment of cutaneous *Acanthamoeba* infection in a lung transplant recipient. *Transplant Infectious Disease* 9: 51-54. doi:10.1111/j.1399-3062.2006.00159.x
- [95] Galarza C., Ramos W., Gutierrez E.L., Ronceros G., Teran M., Uribe M., Navincopa M., Ortega-Loayza A.G. 2009. Cutaneous acanthamebiasis infection in immunocompetent and immunocompromised patients. *International Journal of Dermatology* 48: 1324-1329. doi:10.1111/j.1365-4632.2008.03786.x
- [96] Im K.I., Kim D.S. 1998. Acanthamoebiasis in Korea: two new cases with clinical cases review. *Yonsei Medical Journal* 39: 478-484. doi:10.3349/ymj.1998.39.5.478
- [97] Kaul D.R., Lowe L., Visvesvara G.S., Farmen S., Khaled Y.A., Yanik G.A. 2008. *Acanthamoeba* infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole. *Transplant Infectious Disease* 10: 437-441. doi:10.1111/j.1399-3062.2008.00335.x
- [98] Steinberg J.P., Galindo R.L., Kraus E.S., Ghanem K.G. 2002. Disseminated acanthamebiasis in a renal transplant recipient with osteomyelitis and cutaneous lesions: case report and literature review. *Clinical Infectious Diseases* 35: e43-e49. doi:10.1086/341973

Received 20 April 2018

Accepted 01 October 2018